Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvia Haas

Showing results (1-10 of 147) with videos related to

Pageof 15
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2006
The use of a surgical patch coated with human coagulation factors in surgical routine: a multicenter postauthorization surveillanceSylvia Haas
Thrombosis and Haemostasis|February 23, 2010
Facts and artefacts of coagulation assays for factor Xa inhibitorsSylvia Haas
European Journal of Haematology|February 4, 2009
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programmeSylvia Haas
Thrombosis Research|June 24, 2003
Medical indications and considerations for future clinical decision makingSylvia Haas
MMW Fortschritte Der Medizin|November 22, 2011
[When can he lift again?]Sylvia Haas
Pharmazie in Unserer Zeit|June 24, 2004
[Anticoagulants--well tried and new. Medical prevention and treatment of thromboembolism]Sylvia Haas
Seminars in Vascular Medicine|June 17, 2004
The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromesSylvia Haas
Hamostaseologie|December 6, 2006
[Obituary: in memoriam Hans Klaus Breddin]Sylvia Haas
Hamostaseologie|January 9, 2019
The Role of Low Molecular Weight Heparins for Venous Thromboembolism Prevention in Medical Patients-What Is New in 2019?Sylvia Haas
Expert Review of Cardiovascular Therapy|July 11, 2017
Gender and atrial fibrillation: what role for real-world registry data?Sylvia Haas
Pageof 15

Showing results (1-10 of 147) with videos related to

Sort By:
Pageof 15
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 27, 2006
The use of a surgical patch coated with human coagulation factors in surgical routine: a multicenter postauthorization surveillanceSylvia Haas
Thrombosis and Haemostasis|February 23, 2010
Facts and artefacts of coagulation assays for factor Xa inhibitorsSylvia Haas
European Journal of Haematology|February 4, 2009
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programmeSylvia Haas
Thrombosis Research|June 24, 2003
Medical indications and considerations for future clinical decision makingSylvia Haas
MMW Fortschritte Der Medizin|November 22, 2011
[When can he lift again?]Sylvia Haas
Pharmazie in Unserer Zeit|June 24, 2004
[Anticoagulants--well tried and new. Medical prevention and treatment of thromboembolism]Sylvia Haas
Seminars in Vascular Medicine|June 17, 2004
The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromesSylvia Haas
Hamostaseologie|December 6, 2006
[Obituary: in memoriam Hans Klaus Breddin]Sylvia Haas
Hamostaseologie|January 9, 2019
The Role of Low Molecular Weight Heparins for Venous Thromboembolism Prevention in Medical Patients-What Is New in 2019?Sylvia Haas
Expert Review of Cardiovascular Therapy|July 11, 2017
Gender and atrial fibrillation: what role for real-world registry data?Sylvia Haas
Pageof 15